OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
60058659

Shandong Jinjing Science & Technology Stock Co Ltd

Commodity ChemicalsVerified

The company's capital structure shows a debt-to-equity ratio of 0.41, indicating a relatively conservative leverage position. However, the liquidity risk is rated as medium, and the current ratio of 0.68 suggests that the company may struggle to meet its short-term obligations with its current assets. The free cash flow is negative at -248.21 million CNY, and the operating cash flow is 299.20 million CNY, indicating that the company is not generating sufficient cash from operations to cover capital expenditures. Profitability is severely underperforming, with a return on equity of -11.23% and a return on assets of -6.45%, both significantly below the industry median for commodity chemicals. The company reported a net loss of 584.76 million CNY, with a gross loss of 18.39 million CNY and an operating loss of 666.09 million CNY. These figures suggest that the company is not only failing to generate profits but is also experiencing declining margins. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to regional economic downturns and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or geographic regions. The company's growth trajectory is negative, with a net loss in the most recent reporting period and a significant decline in earnings per share from the estimated 0.28 CNY to an actual -0.42 CNY. Analysts have issued only one "buy" recommendation, with no strong buy or hold ratings, indicating a lack of confidence in the company's near-term prospects. The absence of positive analyst sentiment further underscores the company's financial challenges. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund operations or invest in growth opportunities. The dilution risk is low, but the company's capital structure and financial performance suggest that it may need to raise additional capital in the future, potentially through equity or debt issuance. Recent events, including the company's financial performance and analyst ratings, indicate a challenging operating environment. The company's negative earnings and declining cash flow suggest that it may need to implement cost-cutting measures or seek external financing to stabilize its operations. The lack of positive developments in the most recent filings or transcripts further supports the view that the company is facing significant operational and financial headwinds.

30-day price · 600586+0.32 (+6.1%)
Low$5.19High$6.09Close$5.54As of25 May, 00:00 UTC
Profile
CompanyShandong Jinjing Science & Technology Stock Co Ltd
Ticker600586.SS
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustryCommodity Chemicals
AI analysis

Business. Shandong Jinjing Science & Technology Stock Co Ltd is a chemical manufacturing company that produces commodity chemicals and generates revenue primarily through the sale of chemical products.

Classification. The company is classified under the Basic Materials economic sector, Chemicals business sector, and Commodity Chemicals industry, with a classification confidence of 0.92.

The company's capital structure shows a debt-to-equity ratio of 0.41, indicating a relatively conservative leverage position. However, the liquidity risk is rated as medium, and the current ratio of 0.68 suggests that the company may struggle to meet its short-term obligations with its current assets. The free cash flow is negative at -248.21 million CNY, and the operating cash flow is 299.20 million CNY, indicating that the company is not generating sufficient cash from operations to cover capital expenditures. Profitability is severely underperforming, with a return on equity of -11.23% and a return on assets of -6.45%, both significantly below the industry median for commodity chemicals. The company reported a net loss of 584.76 million CNY, with a gross loss of 18.39 million CNY and an operating loss of 666.09 million CNY. These figures suggest that the company is not only failing to generate profits but is also experiencing declining margins. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases the company's exposure to regional economic downturns and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or geographic regions. The company's growth trajectory is negative, with a net loss in the most recent reporting period and a significant decline in earnings per share from the estimated 0.28 CNY to an actual -0.42 CNY. Analysts have issued only one "buy" recommendation, with no strong buy or hold ratings, indicating a lack of confidence in the company's near-term prospects. The absence of positive analyst sentiment further underscores the company's financial challenges. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund operations or invest in growth opportunities. The dilution risk is low, but the company's capital structure and financial performance suggest that it may need to raise additional capital in the future, potentially through equity or debt issuance. Recent events, including the company's financial performance and analyst ratings, indicate a challenging operating environment. The company's negative earnings and declining cash flow suggest that it may need to implement cost-cutting measures or seek external financing to stabilize its operations. The lack of positive developments in the most recent filings or transcripts further supports the view that the company is facing significant operational and financial headwinds.
Key takeaways
  • The company is experiencing significant financial distress, with a net loss and negative cash flow from operations.
  • Profitability metrics are severely underperforming, with a return on equity of -11.23% and a return on assets of -6.45%.
  • The company's liquidity position is weak, with a current ratio of 0.68 and a negative net cash position after debt.
  • Analyst sentiment is negative, with only one "buy" recommendation and no strong buy or hold ratings.
  • The company's revenue is concentrated in a single business segment, increasing its exposure to regional and industry-specific risks.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$4.52B
Gross profit-$18.4M
Operating income-$666.1M
Net income-$584.8M
R&D
SG&A
D&A
SBC
Operating cash flow$299.2M
CapEx-$79.7M
Free cash flow-$248.2M
Total assets$9.06B
Total liabilities$3.86B
Total equity$5.21B
Cash & equivalents
Long-term debt$2.13B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$5.21B
Net cash-$2.13B
Current ratio0.7
Debt/Equity0.4
ROA-6.5%
ROE-11.2%
Cash conversion-51.0%
CapEx/Revenue-1.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
Metric600586Activity
Op margin-14.7%5.5% medp25 -0.0% · p75 10.8%bottom quartile
Net margin-12.9%4.1% medp25 0.1% · p75 8.8%bottom quartile
Gross margin-0.4%20.5% medp25 12.4% · p75 29.7%bottom quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-1.8%-6.2% medp25 -13.4% · p75 -2.6%top quartile
Debt / equity41.0%37.1% medp25 10.3% · p75 82.0%above median
Observations
IR observations
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.28 CNY
Last actual EPS-0.42 CNY
Mean revenue estimate6,256,000,000 CNY
Last actual revenue4,520,492,000 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-25 04:47 UTC#8230c0fd
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 00:28 UTCJob: efaffb5b